People with multiple sclerosis (MS) spend a significantly greater number of work days each year on sick leave or disability pay than do the general population — including in the years before they are formally diagnosed, a Swedish study found. Though the number of missed work days rises in…
A variant of the HLA-DPB1 gene — called HLA-DPB1*04 — appears to protect people from developing multiple sclerosis (MS) either in childhood or as adults, a study from Greece suggests.
Tysabri (natalizumab) is effective at reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS) and is rarely associated with poor clinical outcomes, a real-life and multiyear observational study reports. The study, “Long-term effect of natalizumab in patients with RRMS: TYSTEN…
Low doses of the anesthetic ketamine could help treat fatigue in people with multiple sclerosis (MS), according to results from a small Phase 1/2 clinical trial. Trial findings were published in the study, “Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of…
An interactive video game was more effective than a word game at improving processing speeds in multiple sclerosis (MS) patients with cognitive difficulties, and gains measured were longer lasting, a small clinical trial reports. These results were in the study “A novel in-home digital treatment to…
Assessing the cognitive health of people with multiple sclerosis (MS) can be performed using online telehealth, with results similar to in-person testing, researchers working with a patient group reported. “By assessing memory in patients prior to a clinic visit using a web-based approach, we may be able to meet the…
A vast majority — 7 out of every 10 — healthcare professionals working with multiple sclerosis (MS) patients across the U.K. believe health services are failing to meet their needs throughout the COVID-19 pandemic, according to an online survey conducted by the MS Society and the MS…
Researchers developed a way of using machine learning to identify those cells most important for a given function or task, such as movement, and for evaluating how they respond to potentially restorative treatments. Using Augur, as this method is called, the team was able to identify the neural circuits in…
The U.S. Food and Drug Administration (FDA) has agreed to review Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced.
The thickness of two layers of nerve cells forming the back of the eye, or retina, can be used to distinguish patients with progressing forms of multiple sclerosis (MS) from those with stable disease, a study suggests. The study, “Macular ganglion cell–inner plexiform layer…
Treatment with Tysabri (natalizumab) can lessen disability in people with relapsing-remitting multiple sclerosis (RRMS), a large and real-world study found, supporting “confirmed disability improvement” reported in a pivotal clinical trial. Nearly one-quarter of the 5, 384 patients enrolled, particularly those new to treatment, experienced a decrease of at least one…
To speed research and work on more personalized treatments for serious diseases, Roche and its subsidiary Genentech announced a partnership with PicnicHealth to access its collection of real-world data. Eligible adults with MS in the United States are also being invited to join a multiyear study assembling such…
Banner Life Sciences announced that Bafiertam (monomethyl fumarate) will become available to adults with relapsing forms of multiple sclerosis (MS) in the United States beginning in September. The U.S. Food and Drug Administration (FDA) approved Bafiertam in April as a bioequivalent to Biogen’s Tecfidera…
A multimedia smartphone application designed to precisely inform about exercise and track physical activity led primary or secondary progressive multiple sclerosis (MS) patients to be more active — but no more than a comparison patient group given only a…
The National Multiple Sclerosis Society announced investments of more than $16 million to support 50 new multi-year research projects and training fellowships addressing multiple sclerosis (MS). This latest series of investments, made over the spring, raised to $65 million total global research funding by the society. Although the…
NeuroScientific Biopharmaceuticals (NSB)’s lead candidate EmtinB induces significantly greater myelin regeneration in a cellular model of multiple sclerosis (MS) than the market-leading therapy Copaxone, the company announced. “These results represent a potential breakthrough in the treatment of MS as there are currently no approved therapeutic drugs available to patients that…
The Multiple Sclerosis Association of America (MSAA) teamed with Wondros, a creative production company, to launch COVID-19 and MS Pathfinder, an online platform offering the multiple sclerosis (MS) community accurate and regularly updated information to help in safely navigating the COVID-19 pandemic. Topics covered range from managing MS symptoms…
High levels of neurofilament light chain (NfL) protein circulating in the blood of patients with multiple sclerosis (MS) at an early stage of the disease are linked to higher disability and faster disease progression, a study has found. According to researchers, these findings suggest that NfL — a…
The ongoing COVID-19 pandemic is disrupting vital care and support for those with neurological disorders like multiple sclerosis (MS), according to a recent report from the Neurological Alliance in the U.K. The report is based upon survey responses from over 1,600 people with neurological conditions in that…
More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the disease within 10 years, a global study of those with radiologically isolated syndrome reported. Progression to MS appears to be more likely in those who are younger, have spinal…
Complementary and alternative medicines are increasingly popular among people with multiple sclerosis (MS) in the northwestern United States, a survey found. More than 80% of the 1,000 people who responded to the Oregon Health & Science University (OHSU) survey reported using supplements and exercise to help treat their MS, and…
Progentec has established new licensing agreements with Stanford University and the Oklahoma Medical Research Foundation to commercialize and sell laboratory technologies related to multiple sclerosis (MS), the company announced. The technologies include laboratory tests for the prediction of MS relapses, measurements of MS disease activity, classification of…
The Australian Government’s Medical Research Future Fund (MRFF) has awarded AU$7.1 million (about $4.95 million) to support two projects focused on harnessing the power of artificial intelligence (AI) and machine learning to develop new ways of diagnosing and treating multiple sclerosis (MS) and mental health disorders in young people.
The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other…
JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to remotely monitor their disease activity and treatment response, has received a $50,000 investment through TEDCO’s Builder Fund, the investor announced. MS is caused by inflammation in the…
Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published…
Disability appears to mostly accumulate in people with relapsing forms of multiple sclerosis (MS) in a progressive manner — rather than being due to relapses, a pooled analysis of patients in two Ocrevus (ocrelizumab) clinical trials shows. These findings, indicating that disease progression underlies relapsing MS as well,…
Dragonfly Therapeutics and Bristol Myers Squibb (BMS) announced an expanded partnership focused on discovering and developing treatment candidates for multiple sclerosis (MS) and neuroinflammation targets. The companies have been working together in therapy research and development for cancer and autoimmune diseases using Dragonfly’s proprietary immunotherapy targeting platform.
Switching to Ocrevus (ocrelizumab) within a relatively short period is a safe and effective option for people with relapsing-remitting multiple sclerosis (RRMS) who stop treatment with Tysabri (natalizumab), a small and retrospective analysis suggests. With a median washout period of six weeks between therapies, the 28 patients in this study…
Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…
Get regular updates to your inbox.
